Skip to main content

Advertisement

SpringerLink
Log in

New Indication for Reduction Surgery in Patients with Advanced Hepatocellular Carcinoma with Major Vascular Involvement

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly in patients with tumor thrombi (TT) in the major vessels.

Patients and Methods

From July 1992 to October 2004, 161 patients diagnosed as having advanced HCC with major vascular involvement were seen consecutively at our hospital. Among these patients, 32 (20%) underwent surgical resection [16 complete resection (CR), 16 reductive resection (RR)]. Eighteen patients (11%) received radiotherapy (RT), 73 (45%) underwent transcatheter arterial chemoembolization (TACE) or transcatheter arterial infusion chemotherapy (TAI), 8 (5%) with distant metastases received systemic chemotherapy, and 30 (19%) received palliative therapy.

Results

Excluding the CR group, the patients in the RR group had a higher 1-year survival rate than the other treatment groups. However, there was no significant difference in the overall survival rates of the RR, RT, and TACE/TAI groups. When we evaluated prognostic factors to clarify the indications for RR in the multidisciplinary treatment of patients with advanced HCC with TT, prothrombin activity (PA) was identified as a significant independent preoperative factor for overall survival in the RR group. The survival rate in patients with PA of ≤78% was significantly lower than that of patients with PA of >78% (P = 0.0004). The median survival time of patients with serum PA of >78% who underwent RR was 13.9 months and that of patients who underwent CR was 9.1 months, with no survival difference between the groups.

Conclusion

In advanced HCC with major vascular involvement, patients who had RR with PA of greater 78% achieved a similar survival to those who had CR. The surgeon should still proceed with RR in those patients with serum PA of >78% if CR does not seem feasible on preoperative evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol 1993;9:298–304

    CAS  PubMed  Google Scholar 

  2. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003;138:1198–1206

    PubMed  Google Scholar 

  3. Furuse J, Iwasaki M, Yoshino M, et al. Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 1997;204:787–790

    CAS  PubMed  Google Scholar 

  4. Yamakado K, Tanaka N, Nakatsuka A, et al. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol 1999;30:660–668

    Article  CAS  PubMed  Google Scholar 

  5. Tanaka A, Morimoto T, Yamaoka Y. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996;43:637–643

    CAS  PubMed  Google Scholar 

  6. Fujii T, Takayasu K, Muramatsu Y, et al. Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. J Gastroenterol Hepatol 1995;10:237–240

    Google Scholar 

  7. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751–755

    Article  Google Scholar 

  8. Chen SC, Hsieh MY, Chuang WL, et al. Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 1994;9:1–6

    CAS  PubMed  Google Scholar 

  9. Asahara T, Itamoto T, Kayayama K, et al. Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculature. Hepatogastroenterology 1999;46:1862–1869

    CAS  PubMed  Google Scholar 

  10. Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993;23:105–109

    CAS  PubMed  Google Scholar 

  11. Lee HS, Kim JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997;79:2087–2094

    CAS  PubMed  Google Scholar 

  12. Ando E, Yamashita F, Tanikawa K, et al. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79:1890–1896

    Article  CAS  PubMed  Google Scholar 

  13. Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435–442

    Article  CAS  PubMed  Google Scholar 

  14. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer 2002;95:588–59

    Article  PubMed  Google Scholar 

  15. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001;233:379–384

    CAS  PubMed  Google Scholar 

  16. Satoh S, Ikai I, Honda G, et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery 2000;128:779–783

    Article  CAS  PubMed  Google Scholar 

  17. Poon RTP, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10–24

    Google Scholar 

  18. Ikai I, Yamaoka Y, Yamamoto Y, et al. Surgical intervention for patients with stage – a hepatocellular carcinoma without lymph node metastasis. Ann Surg 1998;227:433–439

    Article  CAS  PubMed  Google Scholar 

  19. Konishi M, Ryu M, Kinoshita T, et al. Surgical treatment of hepatocellular carcinoma with direct removal of the tumor thrombus in the main portal vein. Hepatogastroenterology 2001;48:1421–1424

    CAS  PubMed  Google Scholar 

  20. Lau H, Fan ST, Ng IOL, et al. Long term prognosis after hepatectomy for hepatocellular carcinoma. Cancer 1998;83:2302–2311

    Article  CAS  PubMed  Google Scholar 

  21. Fan ST, Ng IOL, Poon RTP, et al. Hepatectomy for hepatocellular carcinoma. Arch Surg 1999;134:1124–1130

    CAS  PubMed  Google Scholar 

  22. Torzilli G, Makuuchi M, Inoue K, et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients. Arch Surg 1999;134:984–992

    CAS  PubMed  Google Scholar 

  23. Shimada M, Takenaka K, Kawahara N, et al. Surgical treatment strategy for patients with stage ? hepatocellular carcinoma. Surgery 1996;119:517–522

    CAS  PubMed  Google Scholar 

  24. Tanaka A, Morimoto T, Ozaki N, et al. Extension of surgical indication for advanced hepatocellular carcinoma: Is it possible to prolong life span or improve quality of life? Hepatogastroenterology 1996;43:1172–11801

    CAS  PubMed  Google Scholar 

  25. Wu CC, Ho WL, Lin MC, et al. Hepatic resection for bilobar multicentric hepatocellular carcinoma: Is it justified? Surgery 1998;123:270–277

    CAS  PubMed  Google Scholar 

  26. Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603–608

    Article  CAS  PubMed  Google Scholar 

  27. Poon RTP, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70

    Article  CAS  PubMed  Google Scholar 

  28. El-Assal ON, Yamanoi A, Soda Y, et al. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery 1997;122:571–577

    CAS  PubMed  Google Scholar 

  29. Hanazaki K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001;96:1243–1250

    Article  CAS  PubMed  Google Scholar 

  30. Seong J, Park HC, Han KH, et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiation Oncology Biol Phys 2003;55:329–336

    Article  Google Scholar 

  31. Yamada K, Izaki K, Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113–119

    Article  PubMed  Google Scholar 

  32. Sangro B, Herraiz M, Martinez-Gonzalez MA, et al. Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery 1998;124:575–583

    CAS  PubMed  Google Scholar 

  33. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986–1991

    CAS  PubMed  Google Scholar 

  34. Yamamoto K, Takenaka K, Kawahara N, et al. Indication for palliative reduction surgery in advanced hepatocellular carcinoma. The use of a remnant tumor index. Arch Surg 1997;132:120–123

    CAS  PubMed  Google Scholar 

  35. Wakabayashi H, Ushiyama T, Ishimura K, et al. Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions. J Surg Oncol 2003;82:98–103

    Article  PubMed  Google Scholar 

  36. Inoue K, Nakamura T, Kinoshita T, et al. Volume reduction surgery for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:362–366

    PubMed  Google Scholar 

  37. Shimamura Y, Gunven P, Ishii M, et al. Debulking surgery and arterial embolization for unresectable liver cancer. Hepatogastroenterology 1993;40:10–13

    CAS  PubMed  Google Scholar 

  38. Yamamoto M, Iizuka H, Matsuda M, et al. The indications for tumor mass reduction surgery and subsequent multidisciplinary treatments in stage IV hepatocellular carcinoma. Surg Today 1993;23:675–681

    CAS  PubMed  Google Scholar 

  39. Nagano Y, Tanaka K, Togo S, et al. Efficacy of hepatic resection for hepatocellular carcinomas larger than 10 cm. World J Surg 2005;29:66–71

    PubMed  Google Scholar 

  40. Shuto T, Hirohashi K, Kubo S, et al. Efficacy of major hepatic resection for large hepatocellular carcinoma. Hepatogastroenterology 1999;46:413–416

    CAS  PubMed  Google Scholar 

  41. Noguchi T, Kawarada Y, Kitagawa M, et al. Clinicopathologic factors influencing the long-term prognosis following hepatic resection for large hepatocellular carcinoma more than 10cm in diameter. Semin Oncol 1997;24:S6-7–S6-13

    Google Scholar 

  42. Poon RTP, Fan ST, Lo CM, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: Is it justified? Ann Surg 2002;236:602–611

    Article  PubMed  Google Scholar 

  43. Asahara T, Itamoto T, Katayama K, et al. Indications for palliative reduction surgery for hepatocellular carcinoma with multiple intrahepatic metastases. Hiroshima J Med Sci 1998;47:115–120

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatobiliary Pancreatic Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan

    Naoto Gotohda MD, Taira Kinoshita MD, Masaru Konishi MD, Toshio Nakagohri MD & Shinichiro Takahashi MD

  2. Department of Hepatobiliary Pancreatic Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan

    Junji Furuse MD, Hiroshi Ishii MD & Masahiro Yoshino MD

Authors
  1. Naoto Gotohda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taira Kinoshita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaru Konishi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshio Nakagohri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinichiro Takahashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junji Furuse MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Ishii MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahiro Yoshino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoto Gotohda MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gotohda, N., Kinoshita, T., Konishi, M. et al. New Indication for Reduction Surgery in Patients with Advanced Hepatocellular Carcinoma with Major Vascular Involvement. World J. Surg. 30, 431–438 (2006). https://doi.org/10.1007/s00268-005-0250-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-005-0250-3

Keywords

Search

Navigation